<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res</journal-id><journal-title-group><journal-title>Breast Cancer Research : BCR</journal-title></journal-title-group><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22475046</article-id><article-id pub-id-type="pmc">3446392</article-id><article-id pub-id-type="publisher-id">bcr3161</article-id><article-id pub-id-type="doi">10.1186/bcr3161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of cyclin D<sub>1 </sub>gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Lundgren</surname><given-names>Katja</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>lundgren.katja@gmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Brown</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mbrown@doctors.org.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Pineda</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>s.pineda@qmul.ac.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Cuzick</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>j.cuzick@qmul.ac.uk</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Salter</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>janine.salter@icr.ac.uk</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Zabaglo</surname><given-names>Lila</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>lila.zabaglo@icr.ac.uk</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Howell</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>anthony.howell@christie.nhs.uk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Dowsett</surname><given-names>Mitch</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>mitch.dowsett@icr.ac.uk</email></contrib><contrib contrib-type="author" corresp="yes" id="A9"><name><surname>Landberg</surname><given-names>G&#x000f6;ran</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I6">6</xref><email>glandberg@picr.man.ac.uk</email></contrib><on-behalf-of>the TransATAC investigators</on-behalf-of></contrib-group><aff id="I1"><label>1</label>Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malm&#x000f6; University Hospital, SE-205 02 Malm&#x000f6;, Sweden</aff><aff id="I2"><label>2</label>Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology, University of Manchester, Manchester Academic Health Science Centre Paterson Institute for Cancer Research, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK</aff><aff id="I3"><label>3</label>Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Queen Mary University of London, Wolfson Institute of Preventive Medicine, London EC1M 6BQ, UK</aff><aff id="I4"><label>4</label>Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK</aff><aff id="I5"><label>5</label>Royal Marsden Hospital, 237 Fulham Road, London SW3 6JJ, UK</aff><aff id="I6"><label>6</label>Sahlgrenska Cancer Center, University of Gothenburg, 405 30 G&#x000f6;teborg, Sweden</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>4</day><month>4</month><year>2012</year></pub-date><volume>14</volume><issue>2</issue><fpage>R57</fpage><lpage>R57</lpage><history><date date-type="received"><day>5</day><month>8</month><year>2011</year></date><date date-type="rev-recd"><day>18</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>4</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Lundgren et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Lundgren et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://breast-cancer-research.com/content/14/2/R57"/><abstract><sec><title>Introduction</title><p>Gene amplification of <italic>CCND1 </italic>is observed in a subgroup of breast cancers with poor prognosis, whereas overexpression of the protein cyclin D<sub>1 </sub>has been linked to both worse and better clinical outcome. <italic>CCND1 </italic>amplification and protein overexpression have also been associated with resistance to treatment with tamoxifen or even to a potentially detrimental effect of tamoxifen.</p></sec><sec><title>Methods</title><p>To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D<sub>1 </sub>we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. The <italic>CCND1 </italic>amplification status and protein expression of cyclin D<sub>1 </sub>were assessed by chromogenic <italic>in situ </italic>hybridisation and immunohistochemistry, respectively, in 1,155 postmenopausal, oestrogen-receptor-positive breast cancer patients included in the TransATAC substudy.</p></sec><sec><title>Results</title><p>Amplification of <italic>CCND1 </italic>was observed in 8.7% of the tumours and was associated with increased risk of disease recurrence (hazard ratio = 1.61; 95% confidence interval, 1.08 to 2.41) after adjustment for other clinicopathological parameters. In contrast, nuclear expression of cyclin D<sub>1 </sub>protein was associated with decreased recurrence rate (hazard ratio = 0.6; 95% confidence interval, 0.39 to 0.92). The intensity of nuclear or cytoplasmic expression was not of prognostic value. There was no significant interaction between cyclin D<sub>1 </sub>status and treatment efficacy, ruling out any major detrimental effect of tamoxifen in <italic>CCND1</italic>-amplified postmenopausal breast cancer.</p></sec><sec><title>Conclusions</title><p>In summary, <italic>CCND1 </italic>amplification and low nuclear expression of cyclin D<sub>1 </sub>predicted poor clinical outcome in postmenopausal breast cancer patients treated with either anastrozole or tamoxifen.</p></sec><sec><title>Trial Registration</title><p>Current Controlled Trials <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN18233230">ISRCTN18233230</ext-link>.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Hormone dependence is a fundamental hallmark of the majority of breast cancers, and tumour growth can be inhibited either by deprivation of circulating oestrogens or by antagonising the effect of these hormones on their receptors [<xref ref-type="bibr" rid="B1">1</xref>]. The selective oestrogen receptor (ER) modulator tamoxifen has long been the most commonly used adjuvant therapy for patients with advanced hormone-sensitive breast cancer [<xref ref-type="bibr" rid="B2">2</xref>]. In recent years, however, aromatase inhibitors have become an alternative treatment option for postmenopausal women with breast cancer. An aromatase inhibitor acts by interfering with the enzyme that converts androgens to oestrogen, and reduces tumour and systemic oestrogen concentration [<xref ref-type="bibr" rid="B3">3</xref>]. The third-generation selective aromatase inhibitor anastrozole (Arimidex) reduces serum oestradiol to nanomolar concentrations [<xref ref-type="bibr" rid="B4">4</xref>]. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy of anastrozole alone or in combination with the established adjuvant treatment, tamoxifen for 5 years, as adjuvant treatment for postmenopausal women with operable breast cancer [<xref ref-type="bibr" rid="B5">5</xref>]. The study demonstrated that the efficacy of anastrozole was higher compared with tamoxifen alone, and also superior to the combination of both agents [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. After a median follow-up of 10 years, 5 years after completion of treatment, the significant advantage for anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal, ER-positive breast cancer patients was confirmed [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In breast cancer, genetic alterations such as amplifications and deletions occur within the tumour at high frequencies, and a number of these alterations are closely related to poor clinical outcome. One such region of amplification is 11q13, harbouring the cyclin D<sub>1 </sub>gene <italic>CCND1 </italic>[<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Cyclin D<sub>1 </sub>plays a crucial role as a cell cycle regulator, promoting progression through the G<sub>1</sub>-S phase, following complex formation with CDK4/6 and phosphorylation of the retinoblastoma protein [<xref ref-type="bibr" rid="B11">11</xref>]. Various studies have described the oncogenic capacity of cyclin D<sub>1 </sub><italic>in vitro</italic>, and overexpression <italic>in vivo </italic>results in tumour formation [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Overexpression of cyclin D<sub>1 </sub>is observed in approximately 50% of breast cancers [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>], and cyclin D<sub>1 </sub>is one of the most commonly overexpressed proteins in this form of cancer. A number of studies report cyclin D<sub>1 </sub>overexpression to be a predictor of worse prognosis [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>], while others have found an association with an ER-positive phenotype and a better clinical outcome [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. In about 15% of all primary breast cancers, overexpression is due to amplification of the corresponding gene <italic>CCND1 </italic>[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>], and this specific amplification has been linked to poor prognosis [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Despite the presence of ER&#x003b1;, approximately 50% of breast cancers develop resistance to hormonal treatment, a major clinical limitation of breast cancer therapy [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. The mechanisms behind this phenomenon have been extensively studied, and imply a complex signalling network governing ER function and interaction with various co-regulators [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. Cyclin D<sub>1 </sub>is one such co-factor, known to interact with ER&#x003b1; and, independently of oestrogen, activate the receptor and potentially modify oestrogen/anti-oestrogen responses [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Overexpression of cyclin D<sub>1 </sub>has been reported to result in a conformational change in ER&#x003b1; that induces receptor activation in the presence of the novel selective ER modulator arzoxifene, which in turn promotes growth of MCF-7 cells - indicating a change from antagonist to agonist [<xref ref-type="bibr" rid="B28">28</xref>]. This study also suggests that different mechanisms are required to confer resistance depending on the specific anti-oestrogen administered, and that changes in the conformation of ER&#x003b1; play a crucial role in anti-hormonal insensitivity. A similar study demonstrated that overexpression of cyclin D<sub>1 </sub>reversed the growth inhibitory effect of tamoxifen in two ER-positive breast cancer cell lines [<xref ref-type="bibr" rid="B35">35</xref>]. In line with these experimental findings we have previously observed that cyclin D<sub>1 </sub>overexpression was associated with tamoxifen resistance in premenopausal and postmenopausal breast cancer [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Worryingly, amplification of <italic>CCND1 </italic>was further linked to a potentially detrimental effect of tamoxifen in premenopausal breast cancer patients, when compared with randomised control patients not receiving any adjuvant therapy [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>The aim of our study was to characterise the association between <italic>CCND1 </italic>amplification and cyclin D<sub>1 </sub>protein expression and breast cancer recurrence in a large randomised cohort of postmenopausal patients with ER-positive breast cancer treated with endocrine therapy. In addition, we aimed to assess whether there was a significant difference in response to anastrozole versus tamoxifen according to cyclin D<sub>1 </sub>gene and protein status, and thereby to address any potentially unfavourable effects of tamoxifen in subgroups of breast cancer defined by <italic>CCND1 </italic>amplification.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>The ATAC trial originally evaluated the efficacy and safety of 5 years of anastrozole, tamoxifen, or the combination of both treatments in postmenopausal patients presenting with localised breast cancer [<xref ref-type="bibr" rid="B7">7</xref>]. For the TransATAC protocol, formalin-fixed, paraffin-embedded blocks of the primary tumour were collected from as many hormone-receptor-positive patients as possible, from the monotherapy trial arms [<xref ref-type="bibr" rid="B37">37</xref>]. The endpoint for the analyses was any breast cancer recurrence and the median follow-up time was 10 years. The original study was performed according to the Declaration of Helsinki after approval by an institutional review board and ethics committee, and informed consent was obtained from all patients enrolled in the study.</p></sec><sec><title>Immunohistochemistry</title><p>Nine tissue microarrays (TMAs) were used, each originally including from 165 to 200 tumour tissue samples from the patients included in the TransATAC study. This set of TMAs had one tissue core for each patient: a sample set was analysed for cyclin D<sub>1 </sub>protein expression and a set was analysed for <italic>CCND1 </italic>copy number. For detailed description of the TMA assembly we refer to our previously published study [<xref ref-type="bibr" rid="B37">37</xref>]. The TMA slides were deparaffinised, rehydrated and microwave-treated in target retrieval solution pH 9.9 (Dako, Glostrup, Denmark), and were processed in an automated immunostainer (Techmate 500; Dako, Copenhagen, Denmark) using the Envision software (Dako, Glostrup, Denmark). The antibody employed was a mouse monoclonal antibody reactive against human cyclin D<sub>1 </sub>(1:100, clone DSC-6; Dako, Glostrup, Denmark).</p><p>Staining of cyclin D<sub>1 </sub>was assessed as cytoplasmic staining intensity (0 to 2) as well as nuclear staining intensity (0 to 3) and fraction-positive nuclei (0, &#x0003c; 1%, 1 to 9%, 10 to 32%, 33 to 67% and &#x0003e; 67%) according to the Allred Score [<xref ref-type="bibr" rid="B38">38</xref>]. Evaluation was performed by two independent observers (one a pathologist), with the pathologist's score superseding the other observer's at consolidation. Conflicting observations were low (&#x0003c; 5%) for all evaluations made. All immunohistochemical evaluations were performed without knowledge of tumour characteristics. In cases of no evaluation, the tumour cores were either nonrepresentative (that is, no invasive tumour cells) or were missing. This study was carried out and is reported according to REMARK guidelines [<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Chromogenic <italic>in situ </italic>hybridisation</title><p>Chromogenic <italic>in situ </italic>hybridisation (CISH) was performed according to the Zymed SPoT-Light Cyclin D<sub>1 </sub>Probe protocol suited for CISH [<xref ref-type="bibr" rid="B40">40</xref>] using the SPoT-Light Cyclin D<sub>1 </sub>Amplification Probe (Zymed Laboratories, Invitrogen Immunodetection, San Francisco, CA, USA). Pretreatment procedures included heating and enzyme digestion to optimise the CISH performance. Nonamplified cases were classified as 0, cases with up to 8 copies classified as 1 and &#x0003e; 8 copies classified as 2. In statistical analyses, classifications 1 and 2 were both included in the subgroup defined as amplified.</p></sec><sec><title>Statistical analyses</title><p>The primary endpoint for the analyses was time to recurrence (TTR), also known as the recurrence-free interval. TTR was defined as the time from randomisation to first locoregional recurrence, distant recurrence or contralateral disease. Statistical analyses were performed according to a prespecified statistical analysis plan approved by the ATAC Steering Committee. Cox proportional hazards regression models were fitted to TTR, and hazard ratios (HRs) and associated 95% confidence intervals (CIs) were estimated. The statistical tests employed for correlations between cyclin D<sub>1 </sub>variables and clinicopathological parameters were the Armitage's trend test, the Wilcoxon test, the Goodman's test and the Cuzick test [<xref ref-type="bibr" rid="B41">41</xref>]. Multiple hypothesis testing was not corrected for, thus marginal <italic>P </italic>values should be interpreted with caution. The contribution of cyclin D<sub>1 </sub>protein expression was analysed by the change in likelihood ratio chi-squared test (one degree of freedom) univariately and multivariately, in addition to a model with tumour size, nodal status, grade (central) and Ki67 expression, for all patients and nonamplified patients. All hypothesis tests were conducted at the two-sided <italic>P </italic>= 0.05 level. For detailed description of statistical analyses, we refer to a previous report [<xref ref-type="bibr" rid="B42">42</xref>].</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Distribution of <italic>CCND1 </italic>amplification status and cyclin D<sub>1 </sub>protein staining categories</title><p>In the ATAC trial, 5,880 hormone-receptor-positive breast cancer patients were randomly assigned to receive the monotherapy anastrozole or tamoxifen. For the TransATAC protocol, 1,868 patients from the monotherapy arms were initially included. In the present study, 627 patients were not assessable for <italic>CCND1 </italic>amplification status due to missing or damaged tissue cores, and 86 patients were excluded as they did not meet the study criteria of being ER-positive, leaving 1,155 patients assessable for <italic>CCND1 </italic>amplification status. Out of the patients with known amplification status, 1,054 (91.3%) exhibited nonamplified tumours and 101 (8.7%) were amplified (Figure <xref ref-type="fig" rid="F1">1a</xref>). High cyclin D<sub>1 </sub>cytoplasmic intensity was observed in 380 tumours (32.9%), high nuclear cyclin D<sub>1 </sub>intensity in 278 tumours (24.1%), and 190 tumours (16.5%) had &#x0003e; 67% nuclear fraction positivity as detailed in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>. <italic>CCND1 </italic>gene amplification was associated with a higher expression of nuclear cyclin D<sub>1 </sub>(<italic>P </italic>&#x0003c; 0.001) as well as a higher fraction of positive nuclei (<italic>P </italic>&#x0003c; 0.001), but was not significantly correlated to the amount of cytoplasmic protein (<italic>P </italic>= 0.063) (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F1">1b</xref>). Furthermore, positive correlations were observed between nuclear and cytoplasmic components of cyclin D<sub>1 </sub>protein expression.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Chromogenic <italic>in situ </italic>hybridisation and immunohistochemical staining of breast cancer samples</bold>. <bold>(a) </bold>Two copies of the <italic>CCND1 </italic>gene represents nonamplified patients (i). A copy number of 3 to 8 copies was considered a gain (ii). Amplified tumours often exhibit a very high number of <italic>CCND1 </italic>gene copies (iii). <bold>(b) </bold>Low cytoplasmic staining without nuclear cyclin D<sub>1 </sub>expression (i). Low cyclin D<sub>1 </sub>expression in cytoplasm and low fraction-positive nuclei displaying weak staining intensity of most nuclei (ii). Intermediate cytoplasmic expression and fraction-positive nuclei, with nuclei showing moderate staining intensity (iii). High cytoplasmic and nuclear expression of cyclin D<sub>1</sub>, with nuclear fraction &#x0003e; 67% (iv).</p></caption><graphic xlink:href="bcr3161-1"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Associations between <italic>CCND1 </italic>amplification status, cyclin D<sub>1 </sub>protein expression and clinicopathological variables in all patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">All patients</th><th align="left">Cyclin D<sub>1 </sub>cytoplasmic intensity (negative/low, intermediate, high)</th><th align="left">Cyclin D<sub>1 </sub>nuclear intensity (negative/low, intermediate, high)</th><th align="left">Cyclin D<sub>1 </sub>nuclear fraction (&#x0003c; 1%,1 to 9%, 10 to 32%, 33 to 67%, &#x0003e; 67%)</th><th align="left">Tumour grade (well, moderate, poor)</th><th align="left">Tumour size<sup>a </sup>(mm)</th><th align="left">Nodal status (negative, 1 to 3, &#x0003e; 3)</th><th align="left">Ki67<sup>a</sup></th></tr></thead><tbody><tr><td align="left" colspan="2"><italic>CCND1 </italic>amplification</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Nonamplified</td><td align="left">12%, 52%, 36%</td><td align="left">40%, 36%, 24%</td><td align="left">10%, 24%, 27%, 24%, 15%</td><td align="left">23%, 61%, 16%</td><td align="left">18.0</td><td align="left">70%, 23%, 7%</td><td align="left">4.0</td></tr><tr><td align="left">&#x02003;Amplified</td><td align="left">6%, 48%, 46%</td><td align="left">9%, 35%, 56%</td><td align="left">0%, 6%, 18%, 32%, 44%</td><td align="left">9%, 62%, 29%</td><td align="left">19.0</td><td align="left">64%, 26%, 10%</td><td align="left">7.5</td></tr><tr><td/><td align="left">Armitage (<italic>P </italic>= 0.063)</td><td align="left">Armitage (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Armitage (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Armitage (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Wilcoxon (<italic>P </italic>= 0.083)</td><td align="left">Armitage (<italic>P </italic>= 0.341)</td><td align="left">Wilcoxon (<italic>P </italic>&#x0003c; 0.001)</td></tr><tr><td align="left" colspan="2">Cyclin D<sub>1 </sub>cytoplasmic intensity</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Negative/low</td><td/><td align="left">74%, 16%, 10%</td><td align="left">23%, 33%, 26%, 11%, 4%</td><td align="left">26%, 59%, 15%</td><td align="left">17.5</td><td align="left">68%, 24%, 8%</td><td align="left">3.2</td></tr><tr><td align="left">&#x02003;Intermediate</td><td/><td align="left">40%, 36%, 24%</td><td align="left">10%, 24%, 27%, 25%, 14%</td><td align="left">17%, 63%, 20%</td><td align="left">19.0</td><td align="left">64%, 34%, 2%</td><td align="left">4.6</td></tr><tr><td align="left">&#x02003;High</td><td/><td align="left">20%, 43%, 37%</td><td align="left">3%, 16%, 25%, 28%, 28%</td><td align="left">23%, 61%, 16%</td><td align="left">17.0</td><td align="left">74%, 20%, 6%</td><td align="left">5.6</td></tr><tr><td/><td/><td align="left">Goodman = 0.44 (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Goodman = 0.39 (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Goodman = -0.06 (<italic>P </italic>= 0.238)</td><td align="left">Cuzick trend (<italic>P </italic>= 0.010)</td><td align="left">Goodman = -0.12 (<italic>P </italic>= 0.031)</td><td align="left">Cuzick trend (<italic>P </italic>= 0.021)</td></tr><tr><td align="left" colspan="2">Cyclin D<sub>1 </sub>nuclear intensity</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Negative/low</td><td/><td/><td align="left">23%, 33%, 26%, 11%, 4%</td><td align="left">24%, 62%, 14%</td><td align="left">18.0</td><td align="left">67%, 25%, 8%</td><td align="left">2.9</td></tr><tr><td align="left">&#x02003;Intermediate</td><td/><td/><td align="left">1%, 12%, 41%, 36%, 10%</td><td align="left">18%, 65%, 17%</td><td align="left">18.0</td><td align="left">68%, 25%, 7%</td><td align="left">4.8</td></tr><tr><td align="left">&#x02003;High</td><td/><td/><td align="left">0%, 1%, 7%, 37%, 55%</td><td align="left">17%, 59%, 24%</td><td align="left">17.5</td><td align="left">71%, 22%, 7%</td><td align="left">6.3</td></tr><tr><td/><td/><td/><td align="left">Goodman = 0.88 (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Goodman = 0.16 (<italic>P </italic>&#x0003c; 0.001)</td><td align="left">Cuzick trend (<italic>P </italic>= 0.553)</td><td align="left">Goodman = -0.05 (<italic>P </italic>= 0.327)</td><td align="left">Cuzick trend (<italic>P </italic>&#x0003c; 0.001)</td></tr><tr><td align="left" colspan="2">Cyclin D<sub>1 </sub>nuclear fraction</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x0003c; 1%</td><td/><td/><td/><td align="left">18%, 68%, 14%</td><td align="left">20.0</td><td align="left">2%, 29%, 9%</td><td align="left">2.8</td></tr><tr><td align="left">&#x02003;1 to 9%</td><td/><td/><td/><td align="left">23%, 62%, 15%</td><td align="left">18.0</td><td align="left">68%, 25%, 7%</td><td align="left">2.7</td></tr><tr><td align="left">&#x02003;10 to 32%</td><td/><td/><td/><td align="left">24%, 59%, 17%</td><td align="left">18.0</td><td align="left">71%, 25%, 4%</td><td align="left">4.4</td></tr><tr><td align="left">&#x02003;33 to 67%</td><td/><td/><td/><td align="left">20%, 59%, 21%</td><td align="left">18.0</td><td align="left">70%, 21%, 9%</td><td align="left">4.9</td></tr><tr><td align="left">&#x02003;&#x0003e; 67%</td><td/><td/><td/><td align="left">12%, 68%, 20%</td><td align="left">16.0</td><td align="left">68%, 24%, 8%</td><td align="left">5.9</td></tr><tr><td/><td/><td/><td/><td align="left">Cuzick trend (<italic>P </italic>= 0.005)</td><td align="left">Spearman &#x003c1; = -0.04 (<italic>P </italic>= 0.162)</td><td align="left">Cuzick trend (<italic>P </italic>= 0.694)</td><td align="left">Spearman &#x003c1; = 0.22 (<italic>P </italic>&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>Tests used: Armitage's trend test, Wilcoxon test, Goodman's test, Spearman correlation test and Cuzick test. <sup>a</sup>Median value for each category.</p></table-wrap-foot></table-wrap></sec><sec><title><italic>CCND1 </italic>gene amplification and patient prognosis</title><p>Initially we studied the association between <italic>CCND1 </italic>amplification status and TTR. Survival plots showed that patients exhibiting <italic>CCND1</italic>-amplified tumours had an increased risk of recurrence compared with patients showing nonamplified tumours (HR = 2.04; 95% CI, 1.37 to 3.03; &#x003c7;<sub>1</sub><sup>2 </sup>= 10.51; <italic>P </italic>&#x0003c; 0.001, univariate) (Figure <xref ref-type="fig" rid="F2">2a</xref>). Even when adjusting for the effects of tumour size, nodal status, grade (central) and Ki67 expression, amplification of <italic>CCND1 </italic>was significantly associated with an increased risk of recurrence (HR = 1.61; 95% CI, 1.08 to 2.41; <italic>P </italic>= 0.03) (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Kaplan-Meier plots of recurrence risk over time in all patients</bold>. <bold>(a) </bold>Risk of recurrence was increased for patients exhibiting <italic>CCND1</italic>-amplified breast cancers compared with nonamplified. <bold>(b), (c) </bold>No significant difference was observed between varying intensities of cytoplasmic or nuclear cyclin D<sub>1</sub>. <bold>(d) </bold>Patients showing a nuclear fraction of cyclin D<sub>1 </sub>lower than 1% had an increased risk of recurrence compared with higher expression.</p></caption><graphic xlink:href="bcr3161-2"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Cox proportional Hazards models for estimating the effect on time to recurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Univariate</th><th/><th/><th align="left">Multivariate</th><th/><th/></tr><tr><th/><th colspan="6"><hr/></th></tr><tr><th/><th align="left">HR (95% CI)</th><th align="left">&#x003c7;<sub>1</sub><sup>2</sup></th><th align="left"><italic>P </italic>value</th><th align="left">HR (95% CI)</th><th align="left">&#x003c7;<sub>1</sub><sup>2</sup></th><th align="left"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left">All patients</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;CCND1, amplified vs. nonamplified</td><td align="left">2.04 (1.37 to 3.03)</td><td align="left">10.51</td><td align="left">&#x0003c; 0.001</td><td align="left">1.61 (1.08 to 2.41)</td><td align="left">4.86</td><td align="left">0.030</td></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>cytoplasmic intensity, high vs. remainder</td><td align="left">0.71 (0.51 to 0.98)</td><td align="left">4.43</td><td align="left">0.039</td><td align="left">0.78 (0.56 to 1.09)</td><td align="left">2.15</td><td align="left">0.143</td></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>nuclear intensity, high vs. remainder</td><td align="left">0.91 (0.64 to 1.28)</td><td align="left">0.30</td><td align="left">0.588</td><td align="left">0.85 (0.59 to 1.21)</td><td align="left">0.84</td><td align="left">0.360</td></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>nuclear fraction, 1 to 100% vs. &#x0003c; 1%</td><td align="left">0.58 (0.38 to 0.90)</td><td align="left">5.28</td><td align="left">0.014</td><td align="left">0.60 (0.39 to 0.92)</td><td align="left">4.75</td><td align="left">0.030</td></tr><tr><td align="left">Nonamplified patients</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>cytoplasmic intensity, high vs. remainder</td><td align="left">0.57 (0.39 to 0.82)</td><td align="left">9.57</td><td align="left">0.003</td><td align="left">0.64 (0.44 to 0.95)</td><td align="left">5.21</td><td align="left">0.022</td></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>nuclear intensity, high vs. remainder</td><td align="left">0.88 (0.60 to 1.32)</td><td align="left">0.38</td><td align="left">0.545</td><td align="left">0.84 (0.55 to 1.26)</td><td align="left">0.76</td><td align="left">0.382</td></tr><tr><td align="left">&#x02003;Cyclin D<sub>1 </sub>nuclear fraction, 1 to 100% vs. &#x0003c; 1%</td><td align="left">0.52 (0.34 to 0.81)</td><td align="left">7.29</td><td align="left">0.004</td><td align="left">0.54 (0.35 to 0.85)</td><td align="left">6.36</td><td align="left">0.012</td></tr></tbody></table><table-wrap-foot><p>The &#x003c7;<sub>1</sub><sup>2 </sup>value is based on the likelihood ratio test with the associated <italic>P </italic>values. Multivariate analyses were adjusted for tumour grade, tumour size, nodal status and Ki67. CI, confidence interval; HR, hazard ratio.</p></table-wrap-foot></table-wrap></sec><sec><title>Cyclin D<sub>1 </sub>protein expression and patient prognosis</title><p>We next investigated how cyclin D<sub>1 </sub>protein localisation and expression was related to TTR. There was no significant difference in TTR with relation to cytoplasmic cyclin D<sub>1 </sub>(Figure <xref ref-type="fig" rid="F2">2b</xref>) or cyclin D<sub>1 </sub>nuclear intensity (Figure <xref ref-type="fig" rid="F2">2c</xref> and Table <xref ref-type="table" rid="T2">2</xref>). Surprisingly, a greater fraction of cyclin D<sub>1</sub>-positive nuclei was associated with longer TTR (HR = 0.60; 95% CI, 0.39 to 0.92; <italic>P </italic>= 0.03) when adjusted for the effects of tumour size, nodal status, grade and Ki67 expression (Figures <xref ref-type="fig" rid="F2">2d</xref>, <xref ref-type="fig" rid="F3">3b</xref> and Table <xref ref-type="table" rid="T2">2</xref>). Also, when subcategorising patients into high versus lower subgroups of cytoplasmic cyclin D<sub>1 </sub>there was a trend towards a significant difference in TTR (<italic>P </italic>= 0.055; univariate, HR = 0.71; 95% CI, 0.51 to 0.98; <italic>P </italic>= 0.039) (Figure <xref ref-type="fig" rid="F3">3a</xref> and Table <xref ref-type="table" rid="T2">2</xref>). When focusing on the non-amplified breast cancer samples, high cytoplasmic cyclin D<sub>1 </sub>protein expression was indeed associated with a better outcome (<italic>P </italic>= 0.005) (Figure <xref ref-type="fig" rid="F3">3c</xref> and Table <xref ref-type="table" rid="T2">2</xref>). The data further indicated that the lowest fraction of cyclin D<sub>1</sub>-positive nuclei (&#x0003c; 1%) was associated with shorter TTR compared with subgroups of higher percentage positive nuclei, as illustrated in Figure <xref ref-type="fig" rid="F3">3b, d</xref>. Unfortunately, the number of <italic>CCND1-</italic>amplified cases was too low to analyse survival according to nuclear protein expression; that is, this subgroup contained no cases exhibiting a nuclear protein expression &#x0003c; 1%.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Predicted risk of recurrence over time based on cytoplasmic intensity and nuclear fraction of cyclin D<sub>1</sub>, comparing two subgroups</bold>. <bold>(a) </bold>In all patients, no significant difference in recurrence risk was observed between low and high cytoplasmic expression. <bold>(b) </bold>Patients showing a nuclear fraction of less than 1% positive cyclin D<sub>1 </sub>nuclei had an increased risk of recurrence compared with a fraction of 1 to 100%, in all patients. <bold>(c) </bold>In patients exhibiting nonamplified tumours, high cytoplasmic expression was associated with a reduced risk of recurrence. <bold>(d) </bold>A fraction of cyclin D<sub>1</sub>-positive nuclei lower than 1% was associated with a higher recurrence risk also in patients showing nonamplified tumours.</p></caption><graphic xlink:href="bcr3161-3"/></fig></sec><sec><title>Interactions of cyclin D<sub>1 </sub>and treatment, nodal status and Ki67</title><p>Based on previous reports indicating that amplification of the <italic>CCND1 </italic>gene and cyclin D<sub>1 </sub>overexpression might be associated with tamoxifen resistance or detrimental effects, we wanted to elucidate whether this could be further clarified in the patient cohort of the present study. The subgroup of patients treated with tamoxifen included 571 cases, and the anastrozole-treated subgroup included 584 patients. For <italic>CCND1 </italic>amplification status there was no significant difference in TTR between anastrozole-treated and tamoxifen-treated patients (Figure <xref ref-type="fig" rid="F4">4a</xref>). Moreover, for nonamplified cases there was no difference according to nodal status or Ki67 levels between the treatment arms. For cytoplasmic cyclin D<sub>1 </sub>expression there was an association in TTR according to amplification status (HR = 2.8; 95% CI, 1.2 to 6.4 for the interaction) (Figure <xref ref-type="fig" rid="F4">4b</xref>). In nonamplified breast cancers, however, no significant difference in TTR was observed for treatment (HR = 1.8; 95% CI, 0.8 to 3.9 for the interaction), nodal status (HR = 1.5; 95% CI, 0.7 to 3.2) or Ki67 levels (HR = 1.3; 95% CI, 0.6 to 3.0) (Figure <xref ref-type="fig" rid="F4">4b</xref>). Finally, for the nuclear fraction we observed an association in Ki67 levels for TTR (HR = 3.5; 95% CI, 1.0 to 12.3 for the interaction) (Figure <xref ref-type="fig" rid="F4">4c</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Forest plot showing the effect of <italic>CCND1 </italic>amplification, cytoplasmic and nuclear cyclin D<sub>1 </sub>expression</bold>. <bold>(a) </bold>Amplified against nonamplified breast cancers in the subgroups of treatment, nodal status and Ki67. <bold>(b) </bold>High cytoplasmic intensity against low or intermediate intensity. <bold>(c) </bold>Nuclear fraction of 1 to 100% against &#x0003c; 1% positive nuclei. Reference population for all subgroups was nonamplified patients (except for amplification status). HR, hazard ratio; neg, negative; pos, positive.</p></caption><graphic xlink:href="bcr3161-4"/></fig></sec><sec><title>Cyclin D<sub>1</sub>, <italic>CCND1 </italic>and clinicopathological data</title><p>The <italic>CCND1 </italic>amplification status was positively correlated to tumour grade (<italic>P </italic>&#x0003c; 0.001) and proliferation (defined as Ki67 expression) (<italic>P </italic>&#x0003c; 0.001), but not to nodal status or tumour size (Table <xref ref-type="table" rid="T1">1</xref>). Cytoplasmic cyclin D<sub>1 </sub>expression was inversely correlated to tumour size (all patients; <italic>P </italic>= 0.01) and nodal status (<italic>P </italic>= 0.031), and was positively correlated to proliferation (<italic>P </italic>= 0.021). Both nuclear staining intensity of cyclin D<sub>1 </sub>and fraction-positive nuclei were associated with higher grade (<italic>P </italic>&#x0003c; 0.001 and <italic>P </italic>= 0.005 respectively) and higher proliferation rate (both <italic>P </italic>&#x0003c; 0.001).</p></sec><sec><title>Cyclin D<sub>1</sub>, proliferation and time to recurrence</title><p>Ki67 expression is a common marker used to analyse the proliferation rate in tumour samples, and high proliferation is linked to a more aggressive tumour phenotype. Surprisingly, despite a positive correlation between nuclear cyclin D<sub>1 </sub>expression and Ki67 expression (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F5">5a</xref>), high expression of nuclear cyclin D<sub>1 </sub>was associated with an improved TTR compared with low expression. To further illustrate how a combined proliferation and cyclin D<sub>1 </sub>assessment would be linked to TTR we subdivided patients according to Ki67 expression and nuclear cyclin D<sub>1 </sub>status. Patients with tumours exhibiting low Ki67 expression in association with 1 to 100% cyclin D<sub>1</sub>-positive nuclei (high) were associated with a considerably lower risk of recurrence (<italic>P </italic>&#x0003c; 0.001) (Figure <xref ref-type="fig" rid="F5">5b</xref>) compared with the other subgroups. The subgroups of low cyclin D<sub>1 </sub>include quite low patient numbers and hence the results should be interpreted with caution, but these results suggest that the expression of cyclin D<sub>1 </sub>affects disease outcome independently of proliferation status.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Recurrence risk over time based on the expression of Ki67 and cyclin D<sub>1</sub></bold>. <bold>(a) </bold>Expression of Ki67 increased with increasing percentage of cyclin D<sub>1</sub>-positive nuclei in the breast tumours. <bold>(b) </bold>Kaplan-Meier plot showing that the combination of high Ki67 and low cyclin D<sub>1 </sub>expression was associated with high risk of recurrence (green). Patients exhibiting a high fraction of cyclin D<sub>1</sub>-positive tumour cell nuclei in concurrence with low Ki67 expression showed the lowest risk of recurrence (red).</p></caption><graphic xlink:href="bcr3161-5"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Amplification of the <italic>CCND1 </italic>gene has been associated with a poor patient outcome in previous studies [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B26">26</xref>], whilst controversy regarding overexpression of cyclin D<sub>1 </sub>protein in relation to patient survival still exists. Cyclin D<sub>1 </sub>has been reported to be a prognostic marker in invasive breast cancer and has been associated with both a less aggressive ER-positive phenotype [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B22">22</xref>] and also with an adverse clinical outcome [<xref ref-type="bibr" rid="B18">18</xref>]. These conflicting findings can potentially be explained by the low patient numbers analysed and/or methodological discrepancies. To clarify the importance of cyclin D<sub>1 </sub>in breast cancer we therefore analysed the expression of cyclin D<sub>1 </sub>in different subcellular localisations, using a previously validated antibody [<xref ref-type="bibr" rid="B36">36</xref>], as well as the gene amplification status by the well-established CISH technique in a large, well-characterised randomised patient cohort including more than 1,000 patients with ER-positive breast cancers. Our data support studies indicating that low cyclin D<sub>1 </sub>protein expression as well as <italic>CCND1 </italic>amplification are linked to tumour aggressiveness and increased risk of disease recurrence in ER-positive postmenopausal breast cancer [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. Similar findings have been observed for HER2, where both high expression linked to amplification and low expression are linked to poor outcome [<xref ref-type="bibr" rid="B43">43</xref>].</p><p>Amplification of <italic>CCND1 </italic>was observed in 8.7% of the tumours, which is slightly lower than the frequency of 10 to 15% generally reported, even though some groups have demonstrated a lower percentage of <italic>CCND1</italic>-amplified tumours [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. The slightly lower fraction of <italic>CCND1</italic>-amplified cases may be due to all patients being ER-positive or due to methodological differences and different cutoff points for defining amplification between studies. In addition, the use of TMAs has certain limitations; however, this technique is indispensable when analysing large patient materials and is today a well-accepted approach for large-scale tumour sample analysis. In agreement with previous studies, gene amplification of <italic>CCND1 </italic>was associated with an overall adverse clinical outcome. The observed positive correlation between nuclear cyclin D<sub>1 </sub>expression and tumour grade and proliferation suggests a link between cyclin D<sub>1 </sub>and aggressive disease. In contrast, both higher nuclear expression and high cytoplasmic expression of cyclin D<sub>1 </sub>was instead associated with a decreased recurrence risk. Despite a positive association between cyclin D<sub>1 </sub>protein and <italic>CCND1 </italic>amplification status, both low nuclear fraction of cyclin D<sub>1 </sub>and <italic>CCND1 </italic>amplification were linked to earlier disease recurrence independently of other clinicopathological parameters - hence both factors serve as prognostic markers in endocrine-treated, ER-positive postmenopausal breast cancer. In patients not displaying <italic>CCND1 </italic>amplification, cytoplasmic expression of cyclin D<sub>1 </sub>was also an independent marker for longer TTR, indicating that the true prognostic value of cyclin D<sub>1 </sub>protein expression may be obscured by the <italic>CCND1</italic>-amplified cases: the clinicopathological significance of cyclin D<sub>1 </sub>expression might thus be best considered separately for amplified and nonamplified cases.</p><p>Apart from the role as a prognostic marker, cyclin D<sub>1 </sub>has been proposed as a predictive factor for tamoxifen response, as illustrated by poor clinical outcome in patients with ER-positive tumours with high cyclin D<sub>1 </sub>expression treated with tamoxifen [<xref ref-type="bibr" rid="B46">46</xref>]. These findings together with numerous experimental reports [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>] support that cyclin D<sub>1 </sub>overexpression might abrogate the response to tamoxifen, as previously reported by our group and others [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. Our earlier discoveries have nevertheless been made in cohorts where patients were randomly assigned to receive either no adjuvant treatment or to receive tamoxifen [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. In the present study we compared the two endocrine therapies anastrozole and tamoxifen in relation to disease recurrence and cyclin D<sub>1 </sub>status, but there were no untreated control patients. There was no significant difference in treatment response between these two adjuvant therapies by stratification for cyclin D<sub>1 </sub>status, indicating that cyclin D<sub>1 </sub>is not a predictive marker for differences in response to anastrozole versus tamoxifen. No conclusions can be drawn, however, regarding cyclin D<sub>1 </sub>as a marker for general endocrine treatment resistance, since no untreated patients were available for analysis within the TransATAC study. Moreover, differences in tamoxifen response in relation to cyclin D<sub>1 </sub>in postmenopausal versus premenopausal breast cancer might exist. Our previous study reporting a potential unfavourable effect of tamoxifen included premenopausal patients exclusively, whereas this study focused exclusively on postmenopausal breast cancer cases and has shown no detrimental effect since the results for the two endocrine therapies were similar.</p><p>The relationship between cyclin D<sub>1</sub>, proliferation and prognosis is quite complex, with a positive correlation between cyclin D<sub>1 </sub>and Ki67 - Ki67 is associated with shorter TTR, while cyclin D<sub>1 </sub>is associated with longer TTR. Patients showing low expression of Ki67 had a longer TTR with the highest levels of cyclin D<sub>1 </sub>expression, whereas patients exhibiting higher levels of Ki67 had the shortest TTR with the lowest levels of cyclin D<sub>1 </sub>expression. Multivariate analysis identified the fraction cyclin D<sub>1</sub>-positive nuclei as a predictor of outcome independently of other clinicopathological parameters such as Ki67. These results suggest that, irrespective of proliferation status, intermediate to high expression of cyclin D<sub>1 </sub>results in a prolonged TTR in ER-positive, postmenopausal breast cancer patients. Similar results were observed in our previous study of randomised material from premenopausal breast cancer patients [<xref ref-type="bibr" rid="B47">47</xref>]. The relationship between cyclin D<sub>1</sub>, proliferation and prognosis hence seems to be complex, and this could in part be explained by potential additional functions for cyclin D<sub>1 </sub>unrelated to proliferation control, as well as co-amplification and co-deletion of specific genes on chromosome 11q13, the locus harbouring <italic>CCND1</italic>.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This study confirms that the cyclin D<sub>1 </sub>status provides independent prognostic information regarding ER-positive, postmenopausal breast cancers, supporting its emerging role as a biomarker that might be useful in the clinic. Our results demonstrate that high expression of cyclin D<sub>1 </sub>was associated with a reduced risk of recurrences, whereas amplification of the <italic>CCND1 </italic>gene was linked to an aggressive disease. Finally, no difference in response to anastrozole compared with tamoxifen was observed according to expression of cyclin D<sub>1 </sub>gene amplification or protein expression.</p></sec><sec><title>Abbreviations</title><p>ATAC: Arimidex, Tamoxifen, Alone or in Combination; CI: confidence interval; CISH: chromogenic <italic>in situ </italic>hybridisation; ER: oestrogen receptor; HR: hazard ratio; TMA: tissue microarray; TTR: time to recurrence.</p></sec><sec><title>Competing interests</title><p>JC has acted as a consultant and/or on advisory boards for AstraZeneca and received commercial research grants from AstraZeneca. AH has acted as a consultant and/or on advisory boards for AstraZeneca, GSK, Pfizer, Roche and Amgen, and has received honoraria from AstraZeneca. MD receives paid advisory boards and research funding from each of Novartis, AstraZeneca and Roche. The remaining authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>KL carried out the immunohistochemical and CISH assessments, participated in the study design and drafted the manuscript. MB assisted with evaluation of the immunohistochemistry. SP performed the statistical analyses. JC designed the clinical trial, assembled trial data, and planned and performed the statistical analyses. JS assembled trial data. LZ assembled trial data. AH designed the clinical trial and collected clinical data. MD designed the clinical trial and collected clinical data, and initiated and conceived the current study. GL initiated and conceived the study, supervised interpretation of the data, took part in the immunohistochemical assessments and evaluation of CISH, and helped to draft the manuscript. All authors took part in data interpretation, writing the report and approval of the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Supplementary </bold>Table <xref ref-type="table" rid="T1">1</xref><bold>showing the distribution of cyclin D<sub>1 </sub>staining categories</bold>.</p></caption><media xlink:href="bcr3161-S1.DOC" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors thank Elise Nilsson for excellent technical implementation. This study was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Malm&#x000f6; University Hospital Research and Cancer Funds, Lund University Research Funds, South Swedish and South-East Swedish Breast Cancer groups and Breakthrough Breast Cancer Unit, Manchester, UK.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><article-title>Recent advances in endocrine therapy of breast cancer</article-title><source>BMJ</source><year>1997</year><volume>315</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1136/bmj.315.7112.863</pub-id><pub-id pub-id-type="pmid">9353509</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Haybittle</surname><given-names>JL</given-names></name><name><surname>Davies</surname><given-names>C</given-names></name><name><surname>Mason</surname><given-names>BH</given-names></name><name><surname>Wilcken</surname><given-names>N</given-names></name><name><surname>Ploner</surname><given-names>M</given-names></name><name><surname>Yosef</surname><given-names>HMA</given-names></name><name><surname>Lobelle</surname><given-names>JP</given-names></name><name><surname>Peek</surname><given-names>U</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Mauriac</surname><given-names>L</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Price</surname><given-names>JJ</given-names></name><name><surname>Hupperets</surname><given-names>PSGJ</given-names></name><name><surname>Ragaz</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>RB</given-names></name><name><surname>Abu-Zahra</surname><given-names>HT</given-names></name><name><surname>Portnoj</surname><given-names>SM</given-names></name><name><surname>Riley</surname><given-names>D</given-names></name><name><surname>Gordon</surname><given-names>NH</given-names></name><name><surname>Davis</surname><given-names>HL</given-names></name><name><surname>Naja</surname><given-names>A</given-names></name><name><surname>Romestaing</surname><given-names>P</given-names></name><name><surname>Dubois</surname><given-names>JB</given-names></name><name><surname>Mace-Lesec'h</surname><given-names>J</given-names></name><name><surname>Rambert</surname><given-names>P</given-names></name><name><surname>Barkmanova</surname><given-names>J</given-names></name><name><surname>Owen</surname><given-names>JR</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name><name><surname>Swindell</surname><given-names>R</given-names></name><article-title>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1687</fpage><lpage>1717</lpage><pub-id pub-id-type="pmid">15894097</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Brodie</surname><given-names>AM</given-names></name><name><surname>Njar</surname><given-names>VC</given-names></name><article-title>Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications</article-title><source>J Steroid Biochem Mol Biol</source><year>1998</year><volume>66</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0960-0760(98)00022-3</pub-id><pub-id pub-id-type="pmid">9712406</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Geisler</surname><given-names>J</given-names></name><name><surname>King</surname><given-names>N</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Ottestad</surname><given-names>L</given-names></name><name><surname>Lundgren</surname><given-names>S</given-names></name><name><surname>Walton</surname><given-names>P</given-names></name><name><surname>Kormeset</surname><given-names>PO</given-names></name><name><surname>Lonning</surname><given-names>PE</given-names></name><article-title>Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer</article-title><source>Br J Cancer</source><year>1996</year><volume>74</volume><fpage>1286</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1038/bjc.1996.531</pub-id><pub-id pub-id-type="pmid">8883419</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Budzar</surname><given-names>AU</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Houghton</surname><given-names>JH</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name><name><surname>Sahmoud</surname><given-names>T</given-names></name><article-title>Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>2131</fpage><lpage>2139</lpage><pub-id pub-id-type="pmid">12090977</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Hoctin-Boes</surname><given-names>G</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Locker</surname><given-names>GY</given-names></name><name><surname>Tobias</surname><given-names>JS</given-names></name><article-title>Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>60</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15639680</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Sestak</surname><given-names>I</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><article-title>Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70257-6</pub-id><pub-id pub-id-type="pmid">21087898</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Ormandy</surname><given-names>CJ</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Daly</surname><given-names>RJ</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><article-title>Cyclin D<sub>1</sub>, EMS1 and 11q13 amplification in breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2003</year><volume>78</volume><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1023/A:1023033708204</pub-id><pub-id pub-id-type="pmid">12755491</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Ball</surname><given-names>JR</given-names></name><name><surname>Macmillan</surname><given-names>RD</given-names></name><name><surname>Kenny</surname><given-names>FS</given-names></name><name><surname>Prall</surname><given-names>OW</given-names></name><name><surname>Campbell</surname><given-names>DH</given-names></name><name><surname>Cornish</surname><given-names>AL</given-names></name><name><surname>McClelland</surname><given-names>RA</given-names></name><name><surname>Daly</surname><given-names>RJ</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><article-title>EMS1 gene expression in primary breast cancer: relationship to cyclin D<sub>1 </sub>and oestrogen receptor expression and patient survival</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>1053</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202023</pub-id><pub-id pub-id-type="pmid">9747885</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>LA</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Bismar</surname><given-names>TA</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><article-title>Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers</article-title><source>Breast Cancer Res Treat</source><year>2010</year><volume>121</volume><fpage>347</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s10549-009-0479-x</pub-id><pub-id pub-id-type="pmid">19636701</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name><article-title>CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>1501</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1101/gad.13.12.1501</pub-id><pub-id pub-id-type="pmid">10385618</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Kahn</surname><given-names>SM</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Cacace</surname><given-names>AM</given-names></name><name><surname>Infante</surname><given-names>AS</given-names></name><name><surname>Doi</surname><given-names>S</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name><article-title>Overexpression of cyclin D<sub>1 </sub>in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression</article-title><source>Oncogene</source><year>1993</year><volume>8</volume><fpage>3447</fpage><lpage>3457</lpage><pub-id pub-id-type="pmid">8247550</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Kahn</surname><given-names>SM</given-names></name><name><surname>Schieren</surname><given-names>I</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name><article-title>Antisense to cyclin D<sub>1 </sub>inhibits growth and reverses the transformed phenotype of human esophageal cancer cells</article-title><source>Oncogene</source><year>1995</year><volume>11</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">7630641</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>TC</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Zukerberg</surname><given-names>L</given-names></name><name><surname>Lees</surname><given-names>E</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>EV</given-names></name><article-title>Mammary hyperplasia and carcinoma in MMTV-cyclin D<sub>1 </sub>transgenic mice</article-title><source>Nature</source><year>1994</year><volume>369</volume><fpage>669</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/369669a0</pub-id><pub-id pub-id-type="pmid">8208295</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Fantl</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name><name><surname>Dickson</surname><given-names>C</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><article-title>Amplification and overexpression of cyclin D<sub>1 </sub>in breast cancer detected by immunohistochemical staining</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>1812</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">8137296</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Bartkova</surname><given-names>J</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>H</given-names></name><name><surname>Lutzhoft</surname><given-names>D</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name><article-title>Cyclin D<sub>1 </sub>protein expression and function in human breast cancer</article-title><source>Int J Cancer</source><year>1994</year><volume>57</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910570311</pub-id><pub-id pub-id-type="pmid">8168995</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>McIntosh</surname><given-names>GG</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>Milton</surname><given-names>I</given-names></name><name><surname>Steward</surname><given-names>M</given-names></name><name><surname>Parr</surname><given-names>AH</given-names></name><name><surname>Thomas</surname><given-names>MD</given-names></name><name><surname>Henry</surname><given-names>JA</given-names></name><name><surname>Angus</surname><given-names>B</given-names></name><name><surname>Lennard</surname><given-names>TW</given-names></name><name><surname>Horne</surname><given-names>CH</given-names></name><article-title>Determination of the prognostic value of cyclin D<sub>1 </sub>overexpression in breast cancer</article-title><source>Oncogene</source><year>1995</year><volume>11</volume><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">7675447</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Kenny</surname><given-names>FS</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Gee</surname><given-names>JM</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><article-title>Overexpression of cyclin D<sub>1 </sub>messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>2069</fpage><lpage>2076</lpage><pub-id pub-id-type="pmid">10473088</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Michalides</surname><given-names>R</given-names></name><name><surname>Hageman</surname><given-names>P</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Houben</surname><given-names>L</given-names></name><name><surname>Wientjens</surname><given-names>E</given-names></name><name><surname>Klompmaker</surname><given-names>R</given-names></name><name><surname>Peterse</surname><given-names>J</given-names></name><article-title>A clinicopathological study on overexpression of cyclin D<sub>1 </sub>and of p53 in a series of 248 patients with operable breast cancer</article-title><source>Br J Cancer</source><year>1996</year><volume>73</volume><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/bjc.1996.128</pub-id><pub-id pub-id-type="pmid">8611372</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Gregory</surname><given-names>W</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Millis</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name><article-title>Cyclin D<sub>1 </sub>and prognosis in human breast cancer</article-title><source>Int J Cancer</source><year>1996</year><volume>69</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19960422)69:2&#x0003c;92::AID-IJC4&#x0003e;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">8608989</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Stendahl</surname><given-names>M</given-names></name><name><surname>Kronblad</surname><given-names>A</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Emdin</surname><given-names>S</given-names></name><name><surname>Bengtsson</surname><given-names>NO</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><article-title>Cyclin D<sub>1 </sub>overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>1942</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601831</pub-id><pub-id pub-id-type="pmid">15138475</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>TS</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Hong</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Paik</surname><given-names>NS</given-names></name><article-title>Prognostic value of combined analysis of cyclin D<sub>1 </sub>and estrogen receptor status in breast cancer patients</article-title><source>Pathol Int</source><year>2003</year><volume>53</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1827.2003.01441.x</pub-id><pub-id pub-id-type="pmid">12588434</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Naidu</surname><given-names>R</given-names></name><name><surname>Wahab</surname><given-names>NA</given-names></name><name><surname>Yadav</surname><given-names>MM</given-names></name><name><surname>Kutty</surname><given-names>MK</given-names></name><article-title>Expression and amplification of cyclin D<sub>1 </sub>in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters</article-title><source>Oncol Rep</source><year>2002</year><volume>9</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">11836618</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Dickson</surname><given-names>C</given-names></name><name><surname>Fantl</surname><given-names>V</given-names></name><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Brookes</surname><given-names>S</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><article-title>Amplification of chromosome band 11q13 and a role for cyclin D<sub>1 </sub>in human breast cancer</article-title><source>Cancer Lett</source><year>1995</year><volume>90</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/0304-3835(94)03676-A</pub-id><pub-id pub-id-type="pmid">7720042</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Buckley</surname><given-names>MF</given-names></name><name><surname>Sweeney</surname><given-names>KJ</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Sini</surname><given-names>RL</given-names></name><name><surname>Manning</surname><given-names>DL</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>deFazio</surname><given-names>A</given-names></name><name><surname>Watts</surname><given-names>CK</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><article-title>Expression and amplification of cyclin genes in human breast cancer</article-title><source>Oncogene</source><year>1993</year><volume>8</volume><fpage>2127</fpage><lpage>2133</lpage><pub-id pub-id-type="pmid">8336939</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Bieche</surname><given-names>I</given-names></name><name><surname>Olivi</surname><given-names>M</given-names></name><name><surname>Nogues</surname><given-names>C</given-names></name><name><surname>Vidaud</surname><given-names>M</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><article-title>Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays</article-title><source>Br J Cancer</source><year>2002</year><volume>86</volume><fpage>580</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600109</pub-id><pub-id pub-id-type="pmid">11870541</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Leonessa</surname><given-names>F</given-names></name><name><surname>Welch</surname><given-names>JN</given-names></name><name><surname>Skaar</surname><given-names>TC</given-names></name><article-title>Cellular and molecular pharmacology of antiestrogen action and resistance</article-title><source>Pharmacol Rev</source><year>2001</year><volume>53</volume><fpage>25</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11171938</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Zwart</surname><given-names>W</given-names></name><name><surname>Rondaij</surname><given-names>M</given-names></name><name><surname>Jalink</surname><given-names>K</given-names></name><name><surname>Sharp</surname><given-names>ZD</given-names></name><name><surname>Mancini</surname><given-names>MA</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name><name><surname>Michalides</surname><given-names>R</given-names></name><article-title>Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D<sub>1</sub></article-title><source>Mol Endocrinol</source><year>2009</year><volume>23</volume><fpage>1335</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1210/me.2008-0268</pub-id><pub-id pub-id-type="pmid">19477949</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Le Goff</surname><given-names>P</given-names></name><name><surname>Montano</surname><given-names>MM</given-names></name><name><surname>Schodin</surname><given-names>DJ</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><article-title>Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>4458</fpage><lpage>4466</lpage><pub-id pub-id-type="pmid">8308015</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Endoh</surname><given-names>H</given-names></name><name><surname>Masuhiro</surname><given-names>Y</given-names></name><name><surname>Kitamoto</surname><given-names>T</given-names></name><name><surname>Uchiyama</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Masushige</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>E</given-names></name><name><surname>Kawashima</surname><given-names>H</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><article-title>Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase</article-title><source>Science</source><year>1995</year><volume>270</volume><fpage>1491</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1126/science.270.5241.1491</pub-id><pub-id pub-id-type="pmid">7491495</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Pietras</surname><given-names>RJ</given-names></name><name><surname>Arboleda</surname><given-names>J</given-names></name><name><surname>Reese</surname><given-names>DM</given-names></name><name><surname>Wongvipat</surname><given-names>N</given-names></name><name><surname>Pegram</surname><given-names>MD</given-names></name><name><surname>Ramos</surname><given-names>L</given-names></name><name><surname>Gorman</surname><given-names>CM</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name><name><surname>Sliwkowski</surname><given-names>MX</given-names></name><name><surname>Slamon</surname><given-names>DJ</given-names></name><article-title>HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>2435</fpage><lpage>2446</lpage><pub-id pub-id-type="pmid">7784095</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Holm</surname><given-names>C</given-names></name><name><surname>Rayala</surname><given-names>S</given-names></name><name><surname>Jirstrom</surname><given-names>K</given-names></name><name><surname>Stal</surname><given-names>O</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><article-title>Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj185</pub-id><pub-id pub-id-type="pmid">16705121</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Zwijsen</surname><given-names>RM</given-names></name><name><surname>Wientjens</surname><given-names>E</given-names></name><name><surname>Klompmaker</surname><given-names>R</given-names></name><name><surname>van der Sman</surname><given-names>J</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Michalides</surname><given-names>RJ</given-names></name><article-title>CDK-independent activation of estrogen receptor by cyclin D<sub>1</sub></article-title><source>Cell</source><year>1997</year><volume>88</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81879-6</pub-id><pub-id pub-id-type="pmid">9039267</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Zwijsen</surname><given-names>RM</given-names></name><name><surname>Buckle</surname><given-names>RS</given-names></name><name><surname>Hijmans</surname><given-names>EM</given-names></name><name><surname>Loomans</surname><given-names>CJ</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><article-title>Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D<sub>1</sub></article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>3488</fpage><lpage>3498</lpage><pub-id pub-id-type="doi">10.1101/gad.12.22.3488</pub-id><pub-id pub-id-type="pmid">9832502</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Wilcken</surname><given-names>NR</given-names></name><name><surname>Prall</surname><given-names>OW</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><article-title>Inducible overexpression of cyclin D<sub>1 </sub>in breast cancer cells reverses the growth-inhibitory effects of antiestrogens</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">9815758</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Jirstrom</surname><given-names>K</given-names></name><name><surname>Stendahl</surname><given-names>M</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Kronblad</surname><given-names>A</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><name><surname>Stal</surname><given-names>O</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><article-title>Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D<sub>1 </sub>gene amplification</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>8009</fpage><lpage>8016</lpage><pub-id pub-id-type="pmid">16140974</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Allred</surname><given-names>C</given-names></name><name><surname>Knox</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>E</given-names></name><name><surname>Salter</surname><given-names>J</given-names></name><name><surname>Wale</surname><given-names>C</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>N</given-names></name><name><surname>Mallon</surname><given-names>E</given-names></name><name><surname>Bishop</surname><given-names>H</given-names></name><name><surname>Ellis</surname><given-names>I</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><name><surname>Carder</surname><given-names>P</given-names></name><name><surname>Cussac</surname><given-names>AL</given-names></name><name><surname>Knox</surname><given-names>F</given-names></name><name><surname>Speirs</surname><given-names>V</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><article-title>Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.9437</pub-id><pub-id pub-id-type="pmid">18227529</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>JM</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><article-title>Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1474</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">10334533</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><article-title>Reporting recommendations for tumor marker prognostic studies (REMARK)</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1093/jnci/dji237</pub-id><pub-id pub-id-type="pmid">16106022</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Arnould</surname><given-names>L</given-names></name><name><surname>Denoux</surname><given-names>Y</given-names></name><name><surname>MacGrogan</surname><given-names>G</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Fiche</surname><given-names>M</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Mathieu</surname><given-names>MC</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Vilain</surname><given-names>MO</given-names></name><name><surname>Couturier</surname><given-names>J</given-names></name><article-title>Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer</article-title><source>Br J Cancer</source><year>2003</year><volume>88</volume><fpage>1587</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600943</pub-id><pub-id pub-id-type="pmid">12771927</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Cuzick</surname><given-names>J</given-names></name><article-title>A Wilcoxon-type test for trend</article-title><source>Stat Med</source><year>1985</year><volume>4</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/sim.4780040112</pub-id><pub-id pub-id-type="pmid">3992076</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="other"><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Wale</surname><given-names>C</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Mallon</surname><given-names>EA</given-names></name><name><surname>Salter</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>E</given-names></name><name><surname>Dunbier</surname><given-names>A</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Bugarini</surname><given-names>R</given-names></name><name><surname>Baehner</surname><given-names>FL</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><article-title>Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>1829</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">20212256</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Dolled-Filhart</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>BL</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><article-title>Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>1445</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">12670887</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Weinstat-Saslow</surname><given-names>D</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Manrow</surname><given-names>RE</given-names></name><name><surname>Lawrence</surname><given-names>JA</given-names></name><name><surname>Bluth</surname><given-names>RF</given-names></name><name><surname>Wittenbel</surname><given-names>KD</given-names></name><name><surname>Simpson</surname><given-names>JF</given-names></name><name><surname>Page</surname><given-names>DL</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name><article-title>Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>1257</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1038/nm1295-1257</pub-id><pub-id pub-id-type="pmid">7489405</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Zukerberg</surname><given-names>LR</given-names></name><name><surname>Yang</surname><given-names>WI</given-names></name><name><surname>Gadd</surname><given-names>M</given-names></name><name><surname>Thor</surname><given-names>AD</given-names></name><name><surname>Koerner</surname><given-names>FC</given-names></name><name><surname>Schmidt</surname><given-names>EV</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><article-title>Cyclin D<sub>1 </sub>(PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D<sub>1 </sub>oncogene</article-title><source>Mod Pathol</source><year>1995</year><volume>8</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">7675778</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Rudas</surname><given-names>M</given-names></name><name><surname>Lehnert</surname><given-names>M</given-names></name><name><surname>Huynh</surname><given-names>A</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Lax</surname><given-names>S</given-names></name><name><surname>Schippinger</surname><given-names>W</given-names></name><name><surname>Dietze</surname><given-names>O</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Stiglbauer</surname><given-names>W</given-names></name><name><surname>Kwasny</surname><given-names>W</given-names></name><name><surname>Grill</surname><given-names>R</given-names></name><name><surname>Stierer</surname><given-names>M</given-names></name><name><surname>Gnant</surname><given-names>MF</given-names></name><name><surname>Filipits</surname><given-names>M</given-names></name><article-title>Cyclin D<sub>1 </sub>expression in breast cancer patients receiving adjuvant tamoxifen-based therapy</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>1767</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4122</pub-id><pub-id pub-id-type="pmid">18347178</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Lehn</surname><given-names>S</given-names></name><name><surname>Tobin</surname><given-names>NP</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Nilsson</surname><given-names>K</given-names></name><name><surname>Sims</surname><given-names>AH</given-names></name><name><surname>Jirstrom</surname><given-names>K</given-names></name><name><surname>Harkonen</surname><given-names>P</given-names></name><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><article-title>Down-regulation of the oncogene cyclin D<sub>1 </sub>increases migratory capacity in breast cancer and is linked to unfavorable prognostic features</article-title><source>Am J Pathol</source><year>2010</year><volume>177</volume><fpage>2886</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.100303</pub-id><pub-id pub-id-type="pmid">20971731</pub-id></mixed-citation></ref></ref-list></back></article>